SCHEMBL1085147

SCHEMBL1085147

Cc1cc(-c2ccc(C(F)(F)F)cc2)cc(C)c1C(=O)N1CCC(N2CCCC2CO)CC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.41
CCR5 P51681 3/20 0.40
BRD4 O60885 1/20 0.39
BRD2 P25440 1/20 0.39
MCHR1 Q99705 6/20 0.38
TRPV1 Q8NER1 1/20 0.38
SPHK2 Q9NRA0 2/20 0.38
SPHK1 Q9NYA1 1/20 0.38
CHRM3 P20309 1/20 0.37
GAA P10253 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
ENPP2 Q13822 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
CHRNB1 P11230 1/20 0.37
CHRNB2 P17787 1/20 0.37
CHRNB4 P30926 1/20 0.37
CHRNA3 P32297 1/20 0.37
CHRNB3 Q05901 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1083711 1.00 KDM1A (0.41) KDM1ACCR5BRD4BRD2MCHR1
SCHEMBL1083713 0.92 TACR1 (0.39) KDM1ACCR5BRD4BRD2TRPV1
SCHEMBL1085071 0.92 TACR1 (0.39) KDM1ACCR5BRD4BRD2TRPV1
SCHEMBL1085174 0.90 TRPV1 (0.47) CCR5TRPV1SPHK2SPHK1CHRM3
SCHEMBL1083706 0.90 TRPV1 (0.47) CCR5TRPV1SPHK2SPHK1CHRM3
SCHEMBL1083701 0.88 EPHX2 (0.43) CCR5CHRM3
SCHEMBL1085279 0.88 EPHX2 (0.43) CCR5CHRM3
SCHEMBL1083733 0.87 CHRNB1 (0.41) TRPV1ENPP2ALDH1A1CHRNB1CHRNB2
SCHEMBL1085252 0.87 CHRNB1 (0.41) TRPV1ENPP2ALDH1A1CHRNB1CHRNB2
SCHEMBL1085077 0.82 CCR5 (0.42) CCR5CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153805-B2 Biaryl derivatives HOFFMANN-LA ROCHE INC. (US) 2012-04-10 US disclosed
US-20090048238-A1 NOVEL BIARYL DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048238-A1 NOVEL BIARYL DERIVATIVES CCR3, CCRL2, CCR2 KDM1A 4321/4885CCR5 5/4885BRD4 418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.